CT & MRI company Medic Vision Imaging Solutions Ltd revealed on Tuesday that it has passed the US Food and Drug Administration (FDA) clearance for latest product, iQMR (intelligent Quick MR), to save cost, improve its productivity and boost patients experience and profitability.
The company said the new iterative image reconstruction technology enhances noisy MRI images and significantly increases SNR (signal to noise ratio). The new technology's capabilities enable the use of short MRI protocols and allow increased productivity, fewer repeating scans as well as better patient's experience.
Concurrently, the iQMR supports MRI scanners of all vendors and models, according to the company.
Following the US FDA's clearance, the company will now launch the iQMR at the upcoming ASNR 56th Annual Meeting. Additionally, Prof Lawrence N Tanenbaum, MD, FACR, VP and director of CT, MR & Advanced Imaging at RadNet, will present the results of a clinical study demonstrating the ability to reduce routine brain exam scan time by 30% without adversely affecting image quality using iQMR.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial